CHRONIC MIGRAINE (PROGRESS STUDY)
QULIPTA demonstrated powerful improvements in change from baseline in mean MMD vs. placebo across 12 weeks1*
QULIPTA significantly reduced mean MMD from baseline vs. placebo (p<0.001; primary endpoint)1
*** p<0.001 vs. placebo
Adapted from the QULIPTA Product Monograph.
Safety information
Click here for additional safety information and for a link to the Product Monograph discussing:
●Relevant warnings and precautions regarding patients with severe hepatic impairment, driving and operating machinery, pregnant and nursing women, and geriatrics.
●Conditions of clinical use, adverse reaction, drug interactions and dosing instructions.
Reference:
1. QULIPTA Product Monograph. AbbVie Corporation.
MMD: monthly migraine days.
* The PROGRESS trial was a phase 3, randomized, multicentre, double-blind, placebo-controlled study that evaluated the efficacy and safety profiles of QULIPTA in patients with chronic migraine who were randomized to receive QULIPTA 60 mg once daily or placebo for 12 weeks.1
For more information
For any questions related to QULIPTA, you can contact AbbVie Medical Information at 1 844 241-5011.
QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
MMD: monthly migraine days.
* The PROGRESS trial was a phase 3, randomized, multicentre, double-blind, placebo-controlled study that evaluated the efficacy and safety profiles of QULIPTA in patients with chronic migraine who were randomized to receive QULIPTA 60 mg once daily or placebo for 12 weeks.1
For more information
For any questions related to QULIPTA, you can contact AbbVie Medical Information at
1 888 241-5011.
QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
CA-QLP-240063A / OC24